Personalized Antiplatelet Therapy in CAD Patients

Exclusion Criteria

• •1. Combined with severe valvular heart disease;
• •2. Combined with severe congenital heart disease;
• •3. Combined hyperthyroidism, anemia and other high-powered heart disease; 4. With pulmonary heart disease;
• •5\. With hypertrophic obstructive cardiomyopathy; 6. Severe hypotension (SBP \<90mmHg or DBP \<60mmHg at enrollment); 7. Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times); 8. Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit); 9. High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases; 10. active peptic ulcer and skin ulcers; 11. A patient who is allergic to clopidogrel, Ticagrelor, or aspirin; 12. Patients with a history of cardiogenic shock within two weeks; 13. pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age; 14. In the past 3 months participated in other clinical researchers; 15. Persons who do not have legal or legal competence; 16. Any condition that the investigator considers unsuitable for participation in the clinical study.